English
Regional settings| Spread | 0.0716 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 0.01 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 2.3692 |
| Open | 2.3592 |
| 1-Year Change | 308.02% |
| Day's Range | 2.2692 - 2.3592 |
Aditxt, Inc., formerly Aditx Therapeutics, Inc., is a biotechnology company. The Company is developing technologies focused on improving the health of the immune system through immune monitoring and reprogramming. The Company’s immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The company’s technology platforms include AditxtScore and AditxtReprogramming. AditxtScore is designed to allow individuals to understand, manage and monitor their immune profiles in order to be informed about attacks on or by their immune system. AditxtScore also assist the medical community in anticipating immune responses and reactions to viruses, bacteria, allergens and transplanted organs. Apoptotic DNA Immunotherapy (ADi) is a nucleic acid-based technology which suppresses only those immune cells involved in the rejection of tissue and organ transplants.
BRIEF: For the nine months ended 30 September 2021, Aditxt Inc revenues was not reported. Net loss increased from $4.5M to $22.3M. Higher net loss reflects General and administrative expenses increase from $2.1M to $11.5M (expense), Research and development increase from $514K to $3.1M (expense), Amortization of debt discount increase from $300K to $1.8M (expense).
